Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy

Objective To assess the use of the cell cycle progression (CCP) score versus actual risk stratification practice in making treatment decisions for prostate cancer patients with locally adverse pathology after radical prostatectomy (RP).